Amphion Innovations plc

Cancellation of Trading on AIM

London and New York, 30 December 2019 - Amphion Innovations plc (AIM: AMP), announces that pursuant to AIM Rule 1, the Company's ordinary shares ("Ordinary Shares") will be cancelled from trading on AIM at 7:00 a.m. on 31 December 2019.

On 27 June 2019, the Company announced that it would not be in a position to publish its audited financial statements for the year ended December 2018 (“2018 Accounts”) by 30 June 2019 in accordance with the AIM Rules for Companies and accordingly suspension of trading in the Ordinary Shares on AIM ("Suspension") occurred on 1 July 2019.

Pursuant to AIM Rule 1, the Company had six months to publish the 2018 Accounts to prevent cancellation of the admission of its Ordinary Shares to trading on AIM. The Company remains highly cash constrained and unfortunately, despite efforts of the Directors the Company has not been able to secure additional funding in time in order to provide clarity over the Company’s going concern status within this timeframe.  Those efforts will continue into the new year and the board looks forward to making a positive announcement about the Company’s future early in the new year.

The Board is considering a number of possibilities for the Company, which include a potential application for the Ordinary Shares to be admitted to trading on AIM at a later point in time.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").


For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Emma Earl (Corporate Finance)
Charles Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

SP Angel Corporate Finance LLP (Joint Corporate Broker)
David Hignell (Corporate Finance)
Rob Rees (Corporate Broking)
+44 (0)20 3470 0470

Walbrook PR
Anna Dunphy / Paul McManus
+44 (0)20 7933 8780

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.

Top